Results 31 to 40 of about 15,173,912 (274)
Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD
Kidney International Reports, 2021 Introduction Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) have an increased risk of thrombotic events and bleeding. Antisense reduction of factor XI (FXI) with IONIS-FXIRx is a novel strategy that may safely reduce the risk of
M. Walsh +9 more
semanticscholar +1 more source
Factor XI deficiency case reports on congenital and acquired Hemophilia C - A case report
Apollo Medicine, 2022 Introduction: Factor XI deficiency or hemophilia C is a very rare coagulation factor deficiency, with a global incidence of 1 in 1 million. Although it is an under-recognized entity, it can cause significant bleeding, resulting in life-threatening ...
Mamta Soni +2 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 Although anticoagulation therapy has evolved from non-specific drugs (i.e., heparins and vitamin K antagonists) to agents that directly target specific coagulation factors (i.e., direct oral anticoagulants, argatroban, fondaparinux), thrombosis remains a
S. Nopp, D. Kraemmer, C. Ay
semanticscholar +1 more source
The new era of anticoagulation: factor XI and XII inhibitors
Bleeding, Thrombosis and Vascular Biology, 2023 The two last decades have witnessed a revolution in the field of anticoagulation, mainly due to the advent of direct anticoagulant with targeted action against single coagulation proteins. However, the residual risk of cardio- and cerebrovascular events,
Domenico Prisco +3 more
doaj +1 more source
Journal of Thrombosis and Haemostasis, 2022 In recent years, many important advances have been seen in anticoagulation therapy. However, bleeding risk is still a major concern. Factor XI (FXI) inhibition has emerged as a potential advantageous target to minimize this risk.
João Presume +3 more
semanticscholar +1 more source
Haemophilia, 2022 Hereditary factor XI (FXI) deficiency is a rare coagulation disorder that may result in excessive bleeding requiring intervention to restore haemostasis.
Xinruo Zhang +5 more
semanticscholar +1 more source
Unusual Comorbid Condition in a Child with Severe Factor XI Deficiency: Spina Bifida [PDF]
Turkish Journal of HematologyAlperen Kahraman +3 more
doaj +2 more sources
What Is the Future of Factor XI Inhibitors?
Circulation, 2022 Parenteral and oral factor XI (FXI) inhibitors, the next potential generation of anticoagulants, are undergoing phase-3 evaluation with the hope that they will be safer than currently available agents.1 This article (1) addresses the unmet needs in ...
J. Weitz, J. Eikelboom
semanticscholar +1 more source
Vascular Health and Risk Management, 2022 During the past decade, emergence of direct oral anticoagulants (DOACs) has drastically improved the prevention of thrombosis. However, several unmet needs prevail in the field of thrombosis prevention, even in the DOACs’ era.
G. Poénou +5 more
semanticscholar +1 more source
A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors
Journal of Thrombosis and Haemostasis, 2021 Several drugs that reduce functional levels of the plasma protease zymogen factor XI (FXI), or that inhibit its activated form (FXIa), are being evaluated as treatments to prevent thrombosis.
O. Salomon, D. Gailani
semanticscholar +1 more source